高血圧の初期治療としてβ-ブロッカーは
Charles S Wiysonge1, Lionel H Opie
1Centre for Evidence-Based Health Care, Stellenbosch University, Cape Town, South Africa.
JAMA
|November 7, 2013
まとめ
ベータブロッカーは高血圧の死亡率を下げないが,プラセボと比較して心血管疾患の減少を控えめにする. カルシウムチャネルブロッカーのような他の薬物クラスでは,より大きな利点があります.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 高血圧管理 高血圧管理について
背景:
- 高血圧は,心血管疾患の主要な危険因子です.
- 初期薬理学的治療戦略は,患者のアウトカムに大きな影響を与えます.
- ベータブロッカーは,高血圧管理の伝統的な選択です.
研究 の 目的:
- 初期高血圧療法としてのベータブロッカーの有効性を評価する.
- ベータブロッカーとプラセボ,無治療,および他の抗高血圧薬のクラスを比較するために.
- すべての原因による死亡率と心血管疾患への影響を評価する.
主な方法:
- ランダム化制御試験の体系的レビューとメタ解析.
- ベータブロッカーとプラセボ,無治療,その他の抗高血圧剤を比較した試験を含む.
- すべての原因による死亡率と主要心血管疾患の発生を報告する研究に焦点を当てます.
主要な成果:
- 最初のベータブロッカーの治療は,全因死亡率の低下を示さなかった.
- プラセボまたは無治療と比較して,心血管イベントの控えめな減少が観察されました.
- カルシウムチャネルブロッカーとRAS阻害剤は,ベータブロッカーよりも優れた心血管イベント減少を示しました.
結論:
- ベータブロッカーは,初期高血圧治療における全因死亡率の低下と関連していません.
- 心血管に何らかの効果がある一方で,他の薬剤のクラスはより効果的です.
- 現在の証拠は伝統的なベータブロッカーに限られており,新しい薬剤に関するデータは欠けている.
関連する概念動画
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
1.0K
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K
01:22Heart Failure Drugs: β-Blockers
3.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
3.0K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:17Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K